DPP-4 inhibitors may reduce drug-resistant epilepsy risk via the gut microbiota and GLP-1 axis
DPP-4 Inhibitors May Offer New Hope for Drug-Resistant Epilepsy
This systematic review explores how DPP-4 inhibitors might mitigate drug-resistant epilepsy through a hypothesized gut microbiota-SCFA-GLP-1…
New research explores how a common class of medications might protect the brain and improve gut health in patients with drug-resistant epile…
GLP-1RAs show lower risk of serious liver events compared with DPP-4 inhibitors in adults with type 2 diabetes
GLP-1 drugs may lower serious liver risks compared to DPP-4 inhibitors in type 2 diabetes
This systematic review and exploratory meta-analysis evaluated incident cirrhosis or composite serious liver events among adults with type 2…
A new analysis suggests GLP-1 receptor agonists might reduce serious liver events compared to DPP-4 inhibitors for adults with type 2 diabet…
Thiazolidinediones show lower hepatocellular carcinoma risk than DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas in this network meta-analysis
New analysis links diabetes drugs to liver outcomes in millions of patients
This network meta-analysis evaluated major adverse liver outcomes among 7124845 adults with type 2 diabetes using glucose-lowering drug clas…
A massive analysis of millions of patients found some diabetes medications linked to lower risks of serious liver events compared to others.
Triple oral therapy with metformin, SGLT-2, and DPP-4 inhibitors lowers HbA1c better than dual regimens in adults with type 2 diabetes
Triple oral diabetes drugs lower blood sugar better than two-drug regimens
A systematic review and meta-analysis of 2,606 adults with type 2 diabetes found that triple oral therapy combining metformin, an SGLT-2 inh…
A large analysis shows that taking three specific oral diabetes medicines together lowers blood sugar more effectively than taking just two …
Narrative review discusses pharmacological and lifestyle interventions for type 2 diabetes and psychological health
New hope for diabetes patients struggling with anxiety and depression
This narrative review examines the relationship between type 2 diabetes and conditions such as anxiety, depression, and cognitive impairment…
Diabetes drugs that control blood sugar might also help improve mood and reduce anxiety for patients living with the condition.
Semaglutide linked to lower neuropsychiatric event risk vs other diabetes drugs in observational study
Semaglutide linked to lower neuropsychiatric risk than other diabetes drugs
This observational cohort study analyzed 63,215 patients with baseline neuropsychiatric conditions across a large US federated data platform…
A large observational study suggests semaglutide may be associated with a lower risk of neuropsychiatric conditions compared to other common…
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
Diabetes Meds Do Not Stop COVID-19
A mini-review of observational studies in patients with type 2 diabetes mellitus found that insulin was linked to worse COVID-19 outcomes, w…
Recent research proves that common diabetes pills do not protect you from getting sick or dying from a virus infection.
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…